Trial reportBMC medicine2018
Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
Trial report in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine.BMC medicine · 2021Trial
- Targeting T-Cell Activation for Malaria Immunotherapy: Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Experimental vaccination by single dose sporozoite injection of blood-stage attenuated malaria parasites.EMBO molecular medicine · 2024Article
- Vaccines and monoclonal antibodies: new tools for malaria control.Clinical microbiology reviews · 2024Review
- Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites.Scientific reports · 2024Article
- The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates forBiomolecules · 2024Review
- Malaria Vaccines: Progress to Date.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- The Complexity of Interferon Signaling in Host Defense against Protozoan Parasite Infection.Pathogens (Basel, Switzerland) · 2023Review
- Advances inPathogens (Basel, Switzerland) · 2023Review
- A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development.Cell reports methods · 2022Article
- Recent clinical trials inform the future for malaria vaccines.Communications medicine · 2021Article
- Whole-Killed Blood-Stage Vaccine: Is It Worthwhile to Further Develop It to Control Malaria?Frontiers in microbiology · 2021Review
- Diversify and Conquer: The Vaccine Escapism ofMicroorganisms · 2020Review
- Potential and Limitations of Cross-Protective Vaccine against Malaria by Blood-Stage Naturally Attenuated Parasite.Vaccines · 2020Article
- Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.The American journal of tropical medicine and hygiene · 2020Review
- [Development of malaria vaccines-state of the art].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Malaria vaccines since 2000: progress, priorities, products.NPJ vaccines · 2020Review
- A genetically hmgb2 attenuated blood stage P. berghei induces crossed-long live protection.PloS one · 2020Article
- The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design.Frontiers in immunology · 2020Review
- Building a better malaria vaccine.Nature · 2019Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe continuing morbidity and mortality associated with infection with malaria parasites highlights the urgent need for a vaccine. The efficacy of sub-unit vaccines tested in clinical trials in malaria-endemic areas has thus far been disappointing, sparking renewed interest in the whole parasite vaccine approach. We previously showed that a chemically attenuated whole parasite asexual blood-stage vaccine induced CD4
methodsIn this current study, we evaluated the immunogenicity and safety of chemically attenuated asexual blood-stage Plasmodium falciparum (Pf) parasites in eight malaria-naïve human volunteers. Study participants received a single dose of 3 × 10
resultsWe demonstrate that Pf asexual blood-stage parasites that are completely attenuated are immunogenic, safe and well tolerated in malaria-naïve volunteers. Following vaccination with a single dose, species and strain transcending Plasmodium-specific T cell responses were induced in recipients. This included induction of Plasmodium-specific lymphoproliferative responses, T cells secreting the parasiticidal cytokines, IFN-γ and TNF, and CD3
conclusionsThis is the first clinical study evaluating a whole parasite blood-stage malaria vaccine. Following administration of a single dose of completely attenuated Pf asexual blood-stage parasites, Plasmodium-specific T cell responses were induced while Pf-specific antibodies were not detected. These results support further evaluation of this chemically attenuated vaccine in humans.
trial registrationTrial registration: ACTRN12614000228684 . Registered 4 March 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.